Dual functional cholinesterase and MAO inhibitors for the treatment of Alzheimer’s disease: synthesis, pharmacological analysis and molecular modeling of homoisoflavonoid derivatives

References

• Blennow K, De Leon M, Zetterberg H. Alzheimer's disease. Lancet 2006;368:387–403
   PubMed Web of Science ®Google Scholar
• Goedert M. Century of Alzheimer's disease. Science 2006;314:777–81
   PubMed Web of Science ®Google Scholar
• Mucke L. Neuroscience: Alzheimer's disease. Nature 2009;461:895–7
   PubMed Web of Science ®Google Scholar
• Bartus R, Dean R, Beer B, et al. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408–14
   PubMed Web of Science ®Google Scholar
• Talesa VN. Acetylcholinesterase in Alzheimer's disease. Mech Ageing Dev 2001;122:1961–9
   PubMed Web of Science ®Google Scholar
• Hardy J, Higgins G. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992;256:184–5
   PubMed Web of Science ®Google Scholar
• Hardy J, Selkoe DJ. Medicine – the amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353–6
   PubMed Web of Science ®Google Scholar
• Hardy J. Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. J Alzheimers Dis 2006;9:151–3
   PubMed Web of Science ®Google Scholar
• Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 2004;3:205–14
   PubMed Web of Science ®Google Scholar
• Beal MF. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 1995;38:357–66
   PubMed Web of Science ®Google Scholar
• Simonian NA, Coyle JT. Oxidative stress in neurodegenerative diseases. Ann Rev Pharmacol 1996;36:83–106
   Google Scholar
• Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006;443:787–95
   PubMed Web of Science ®Google Scholar
• Grundke-Iqbal I, Iqbal K, Tung YC, et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Nat Acad Sci USA 1986;83:4913–17
   PubMed Web of Science ®Google Scholar
• Goedert M, Spillantini MG, Jakes R, et al. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 1989;3:519–26
   PubMed Web of Science ®Google Scholar
• Colombres M, Sagal J, PInestrosa NC. An overview of the current and novel drugs for Alzheimer's disease with particular reference to anti-cholinesterase compounds. Curr Pharm Design 2004;10:3121–30
   PubMed Web of Science ®Google Scholar
• Contestabile A. The history of the cholinergic hypothesis. Behav Brain Res 2011;221:334–40
   PubMed Web of Science ®Google Scholar
• Harel M, Schalk I, Ehret-Sabatier L, et al. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Nat Acad Sci USA 1993;90:9031–5
   PubMed Web of Science ®Google Scholar
• Raves ML, Harel M, Pang Y-P, et al. Structure of acetylcholinesterase complexed with the nootropic alkaloid, (−)-huperzine A. Nat Struct Biol 1997;4:57–63
   PubMedGoogle Scholar
• Kryger G, Silman I, Sussman JL. Structure of acetylcholinesterase complexed with E2020 (Aricept (R)): implications for the design of new anti-Alzheimer drugs. Struct Fold Des 1999;7:297–307
   Google Scholar
• Inestrosa NC, Alvarez A, Perez CA, et al. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 1996;16:881–91
   PubMed Web of Science ®Google Scholar
• Bourne Y, Taylor P, Radic Z, et al. Structural insights into ligand interactions at the acetylcholinesterase peripheral anionic site. Embo J 2003;22:1–12
   PubMed Web of Science ®Google Scholar
• Piazzi L, Rampa A, Bisi A, et al. 3-(4-{benzyl(methyl)amino methyl}-phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy. J Med Chem 2003;46:2279–82
   PubMed Web of Science ®Google Scholar
• Carlier PR, Han YF, Chow ESH, et al. Evaluation of short-tether bis-THA AChE inhibitors. A further test of the dual binding site hypothesis. Bioorg Med Chem 1999;7:351–7
   PubMed Web of Science ®Google Scholar
• Bartolini M, Bertucci C, Cavrini V, et al. Beta-amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem Pharm 2003;65:407–16
   PubMed Web of Science ®Google Scholar
• Walker WH, Kearney EB, Seng RL, et al. The covalently-bound flavin of hepatic monoamine oxidase. 2. Identification and properties of cysteinyl riboflavin. Eur J Biochem/FEBS 1971;24:328–31
   PubMedGoogle Scholar
• Chiba K, Trevor A, Castagnoli N Jr. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Comm 1984;120:574–8
   PubMed Web of Science ®Google Scholar
• Binda C, Newton-Vinson P, Hubalek F, et al. Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat Struct Biol 2002;9:22–6
   PubMedGoogle Scholar
• Edmondson DE, DeColibus L, Binda C, et al. New insights into the structures and functions of human monoamine oxidases A and B. Neural Transm (Vienna, Austria: 1996) 2007;114:703–5
   PubMed Web of Science ®Google Scholar
• Weinreb O, Amit T, Bar-Am O, et al. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol 2010;92:330–44
   PubMed Web of Science ®Google Scholar
• Carreiras MC, Marco JL. Recent approaches to novel anti-Alzheimer therapy. Curr Pharm Des 2004;10:3167–75
   PubMed Web of Science ®Google Scholar
• Sterling J, Herzig Y, Goren T, et al. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. J Med Chem 2002;45:5260–79
   PubMed Web of Science ®Google Scholar
• Perjesi P, Das U, De Clercq E, et al. Design, synthesis and antiproliferative activity of some 3-benzylidene-2,3-dihydro-1-benzopyran-4-ones which display selective toxicity for malignant cells. Eur J Med Chem 2008;43:839–45
   PubMed Web of Science ®Google Scholar
• Desideri N, Olivieri S, Stein ML, et al. Synthesis and anti-picornavirus activity of homo-isoflavonoids. Antiviral Chem Chemoth 1997;8:545–55
   Web of Science ®Google Scholar
• Quaglia MG, Desideri N, Bossu E, et al. Enantioseparation and anti-rhinovirus activity of 3-benzylchroman-4-ones. Chirality 1999;11:495–500
   PubMed Web of Science ®Google Scholar
• Siddalah V, Rao CV, Venkateswarlu S, et al. Synthesis, stereochemical assignments, and biological activities of homoisoflavonoids. Bioorg Med Chem 2006;14:2545–51
   PubMed Web of Science ®Google Scholar
• Hung TM, Cao Van T, Nguyen Tien D, et al. Homoisoflavonoid derivatives from the roots of Ophiopogon japonicus and their in vitro anti-inflammation activity. Bioorg Med Chem Lett 2010;20:2412–16
   PubMed Web of Science ®Google Scholar
• Desideri N, Bolasco A, Fioravanti R, et al. Homoisoflavonoids: natural scaffolds with potent and selective monoamine oxidase-B inhibition properties. J Med Chem 2011;54:2155–64
   PubMed Web of Science ®Google Scholar
• Lu C, Zhou Q, Yan J, et al. A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease. Eur J Med Chem 2013;62:745–53
   PubMed Web of Science ®Google Scholar
• Sun Y, Chen J, Chen X, et al. Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine–Homoisoflavonoid hybrids. Bioorg Med Chem 2013;21:7406–17
   PubMed Web of Science ®Google Scholar
• Secci D, Bolasco A, Carradori S, et al. Recent advances in the development of selective human MAO-B inhibitors: (Hetero)arylidene-(4-substituted-thiazol-2-yl)hydrazines. Eur J Med Chem 2012;58:405–17
   PubMed Web of Science ®Google Scholar
• Ellman GL, Courtney KD, Andres BJ, et al. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88–95
   PubMed Web of Science ®Google Scholar